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ORIGINAL INVESTIGATION
Total cardiovascular or fatal events in people 
with type 2 diabetes and cardiovascular risk 
factors treated with dulaglutide in the REWIND 
trail: a post hoc analysis
Gilles R. Dagenais1* , Lars Rydén2, Lawrence A. Leiter3, Mark Lakshmanan4, Leanne Dyal5, Jeffrey L. Probstfield6, 
Charles Messan Atisso4, Jonathan E. Shaw7, Ignacio Conget8, William C. Cushman9, Patricio Lopez‑Jaramillo10, 
Fernando Lanas11, Ernesto German Cordona Munoz12, Valdis Pirags13, Nana Pogosova14, Jan Basile15, 
Wayne H. H. Sheu16, Theodora Temelkova‑Kurktschiev17, Peter J. Raubenheimer18, Matyas Keltai19, 
Stephanie Hall5, Prem Pais20, Helen M. Colhoun21, Matthew C. Riddle22 and Hertzel C. Gerstein5
Abstract 
Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double blind rand‑
omized trial demonstrated that weekly subcutaneous dulaglutide 1.5 mg, a glucagon like peptide‑1 receptor agonist, 
versus matched placebo reduced the first outcome of major adverse cardiovascular event (MACE), cardiovascular 
death, nonfatal myocardial infarction or nonfatal stroke (594 versus 663 events) in 9901 persons with type 2 diabetes 
and either chronic cardiovascular disease or risk factors, and followed during 5.4 years. These findings were based on 
a time‑to‑first‑event analysis and preclude relevant information on the burden of total major events occurring during 
the trial. This analysis reports on the total cardiovascular or fatal events in the REWIND participants
Methods: We compared the total incidence of MACE or non‑cardiovascular deaths, and the total incidence of 
expanded MACE (MACE, unstable angina, heart failure or revascularization) or non‑cardiovascular deaths between 
participants randomized to dulaglutide and those randomized to placebo. Incidences were expressed as number 
per 1000 person‑years. Hazard ratios (HR) were calculated using the conditional time gap and proportional means 
models.
Results: Participants had a mean age of 66.2 years, 46.3% were women and 31% had previous cardiovascular disease. 
During the trial there were 1972 MACE or non‑cardiovascular deaths and 3673 expanded MACE or non‑cardiovascular 
deaths. The incidence of total MACE or non‑cardiovascular deaths in the dulaglutide and placebo groups was 35.8 
and 40.3 per 1000 person‑years, respectively [absolute reduction = 4.5 per 1000 person‑years; conditional time gap 
HR 0.90 (95% CI, 0.82–0.98) p = 0.020, and proportional means HR 0.89 (95% CI, 0.80–0.98) p = 0.022]. The incidence 
of total expanded MACE or non‑cardiovascular deaths in the dulaglutide and placebo groups was 67.1 and 74.7 per 
1000 person‑years, respectively [absolute reduction = 7.6 per 1000 person‑years; conditional time gap HR 0.93 (95% 
CI, 0.87–0.99) p = 0.023, and proportional means HR 0.90 (95% CI, 0.82–0.99) p = 0.028].
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
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Background
People with diabetes continue to be at high risk for car-
diovascular (CV) events and premature death despite 
the use of established cardioprotective therapies. Large 
randomized placebo-controlled CV outcomes trials have 
therefore been conducted to assess the effects of glucose-
lowering drugs on the hazard of major adverse CV events 
(MACE) defined as nonfatal myocardial infarction, non-
fatal stroke or death from CV causes. Seven such trials 
using glucagon-like peptide-1 receptor agonists (GLP-1 
RAs) have now been published. Four of them reported a 
reduced hazard of MACE [1–4], and a meta-analysis of 
these plus three additional trials whose results were neu-
tral [5–7], reported a statistically significant hazard ratio 
of 0.88 for this outcome [8]. One of these trials was the 
Researching cardiovascular Events with a Weekly INcre-
tin in Diabetes (REWIND) trial, in which the addition 
of a once-weekly subcutaneous injection of dulaglutide 
(1.5  mg) significantly reduced the hazard of MACE by 
12% in 9901 individuals with type 2 diabetes with either 
chronic CV disease or CV risk factors [4]. It also clearly 
demonstrated similar effect sizes in the subgroups with 
(31.5% of participants) and without (68.5% of partici-
pants) known CV disease.
These 7 CV outcomes trials all reported time-to-occur-
rence of the first MACE. Limiting the analysis to time-
to-the first event precludes relevant clinical information 
pertaining to the total event burden experienced by par-
ticipants [9–16]. To assess the impact of dulaglutide on 
total major events in the REWIND trial, we compared 
the composite of total number of MACE or non-CV 
deaths and the composite of total number of expanded 
MACE (MACE, heart failure, unstable angina or revas-
cularization) or non-CV deaths between participants 
randomized to the GLP-1 RA and those randomized to 
placebo.
Methods
Trial design and study population
The trial design, population recruitment, baseline 
characteristics and results have been reported [4, 17, 
18]. In brief, REWIND was a randomized, double-
blind placebo-controlled trial done at 371 sites in 24 
countries. Eligibility criteria included age 50  years 
and older with established or newly diagnosed type 
2 diabetes, a HbA1c ≤ 9.5% on stable doses of up to 2 
oral glucose-lowering drugs, and a body mass index 
(BMI) ≥ 23  kg/m2. In addition, people ≥ age 50 had to 
have CV disease (previous MI, ischemic stroke, revascu-
larization, hospitalization for unstable angina or imag-
ing evidence of myocardial ischemia), those ≥ age 55 
had to have myocardial ischemia or coronary, carotid 
or lower limb arterial stenosis greater than 50%, left 
ventricular hypertrophy, albuminuria or estimated glo-
merular filtration rate (eGFR) < 60  mL/min per 1.73  m2, 
and those ≥ age 60 without evidence of CV or renal dis-
ease needed to have at least 2 of the following risk fac-
tors: hypertension, dyslipidemia, tobacco consumption 
or abdominal obesity. The main exclusion criteria were: 
cancer within the previous 5  years, eGFR < 15  mL/min 
per 1.73  m2, severe hypoglycemia in the previous year, 
liver disease, life expectancy less than 1 year, a CV event 
within the previous 2  months, or plans for revasculari-
sation. The REWIND protocol was approved by Ethics 
Committees at all participating sites and all participants 
provided written informed consent.
Random assignment and follow‑up
REWIND participants were recruited between August 
18, 2011 and August 14, 2013. After a 3-week run-in 
period, eligible participants were randomized to either 
a weekly subcutaneous injection of dulaglutide 1.5  mg 
or matched placebo. Follow-up visits were every 3 to 
6  months to document any CV disease or other health 
problems and to give lifestyle guidance. Among the 
participants randomized to dulaglutide 82.2% took the 
study medication from randomization until either a pri-
mary outcome or final follow-up compared with 83.1% 
of those randomized to placebo. All hospitalizations 
were recorded. REWIND was an event-driven trial with 
a target of at least 1200 confirmed first occurrences of a 
MACE consisting of CV death, nonfatal MI or nonfatal 
stroke. The trial was terminated on August 21, 2018 at 
which point, 1257 people had experienced a confirmed 
first MACE.
Events
The analyses for this report focus on the composite 
of total number of pre-specified MACE or non-CV 
deaths, and the composite of total number of expanded 
MACE outcomes (MACE, heart failure requiring hos-
pitalization or urgent medical visit for treatment, 
Conclusions: These findings suggest that weekly subcutaneous dulaglutide reduced total cardiovascular or fatal 
event burden in people with type 2 diabetes at moderate cardiovascular risk.
Clinical Trial Registration: https ://www.clini caltr ials.gouv. Unique Identifier NCT01394952).
Keys words: Type 2 diabetes, Cardiovascular disease, Glucagon like peptide‑1 receptor agonists
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unstable angina requiring hospitalization for treatment, 
or coronary, carotid or peripheral revascularization) 
or non-CV deaths from any cause. Various combina-
tions of CV or fatal events were also analyzed. All of the 
events reported here were adjudicated by an independ-
ent committee of physicians blinded to the study medi-
cation and used pre-specified definitions [4].
Statistical analyses
Categorical variables were summarized by counts and 
proportions, and continuous variables by means and 
standard deviations (SD). Trends in proportions were 
assessed using the Cochrane-Armitage trend test, and 
trends in means were assessed using simple linear 
regression.  Analyses were performed separately for 
each composite event and focused on the total number 
of events during follow-up, and not the number of peo-
ple with one or more events. Therefore, an individual 
who experienced a heart failure event, followed by a 
MACE, and later on by death from pneumonia would 
be counted as having had 3 events.
Incidence rates of events were estimated as the num-
ber of events per 1000 person-years (py) of follow-up. 
Hazard ratios (HR) and 95% confidence intervals (CI) 
for total MACE or non-CV deaths and total expanded 
MACE or non-CV deaths were estimated using both 
the conditional gap time model [19] and the propor-
tional means model [20]. Cox proportional hazards 
models were used to estimate the HR and 95% CI of 




The REWIND trial randomly assigned 9901 people, 
including 4589 (46.3%) women and 5312 (53.7%) men of 
mean (SD) age 66.2 (6.5) years to the addition of weekly 
subcutaneous injections of either dulaglutide 1.5  mg or 
placebo. Detailed baseline characteristics according to 
randomized treatment group have already been pub-
lished [4]. Baseline characteristics in people who did and 
did not experience one or more MACE or non-CV deaths 
during follow-up are presented in Table  1. Numbers of 
events experienced during follow-up were statistically 
correlated with age, male sex, white background, tobacco 
use, prior CV disease, heart failure, diabetes duration, 
systolic blood pressure, HbA1c, use of beta blockers, 
blood pressure drugs (other than renin-angiotensin sys-
tem modulators), antiplatelet drugs, sulfonylureas and 
insulin, and were inversely related to eGFR, and met-
formin use.
Events during follow‑up
During a median follow-up period of 5.4  years (IQR 
5.1–5.9), 1257 of the 9901 (12.7%) participants experi-
enced at least one MACE, 1918 (19.4%) experienced at 
least one expanded MACE (Additional file 1: Table S1), 
and 465 (4.7%) died from non-CV causes.
By the end of follow-up there were a total of 932 
MACE or non-CV deaths in dulaglutide group partici-
pants (35.8 per 1000 py) and 1040 such outcomes (40.3 
per 1000 py) in placebo group participants (Table  2). 
The total number of MACE or non-CV deaths was, 
therefore, reduced by an absolute amount of 4.5 per 
1000 py in the dulaglutide treatment group. This was 
reflected in a 10% reduced hazard using the condi-
tional time gap model [HR 0.90 (95% CI, 0.82–0.98) 
p = 0.020] and an 11% reduced hazard using the pro-
portional means model [HR 0.89 (95% CI, 080–0.98) 
p = 0.022]. Similar effects were noted within subgroups 
(Additional file  1: Table  S2) defined by age, sex, prior 
CV disease, HbA1c levels, and use of statins, renin-
angiotensin drugs or metformin (interaction P values 
all ≥ 0.15).
During the same period there were a total of 1747 
expanded MACE or non-CV deaths in dulaglutide 
group participants (67.1 per 1000 py) and 1926 such 
outcomes (74.7 per 1000 py) in placebo group partici-
pants. The total number of MACE or non-CV deaths 
was, therefore, reduced by an absolute amount of 7.6 
per 1000 py in the dulaglutide treatment group. This 
was reflected in a 7% reduced hazard using the con-
ditional time gap model [HR 0.93(95% CI (0.87–0.99) 
p = 0.023] and a 10% reduced hazard using the pro-
portional means model [HR 0.90 (95% CI 0.82–0.99) 
p = 0.028]. The mean cumulative event curves for both 
composite outcomes began to diverge after the first year 
and continued diverging until the completion of the 
study showing a lower rate of outcomes in participants 
randomized to dulaglutide than in those randomized 
to placebo (Fig. 1). Similar treatment group differences 
were noted for the composite of total MACE, unstable 
angina or death, total MACE, heart failure or death, 
and total MACE, revascularization or death (Table 2).
As noted in the Tables  3 and Additional file  1: 
Table  S3, there were 1668 first MACE or non-CV 
deaths, comprising 789 in the dulaglutide group and 
879 in the placebo group, [HR 0.88 (95% CI, 0.80–0.97) 
p = 0.011]. A similar pattern was seen for the 2286 first 
expanded MACE or non-CV deaths, that included 1097 
in the dulaglutide group and 1189 in the placebo group, 
[HR 0.91 (95% CI, 0.84–0.99) p = 0.024].
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Discussion
In this post hoc analysis of data from the REWIND trial, 
participants randomized to a once-weekly subcutaneous 
injection of dulaglutide 1.5 mg had a reduced total num-
ber of CV or fatal outcomes in addition to the number 
of first CV or fatal events compared with participants 
Table 1 Distribution of number MACE or non-CV deaths according to baseline characteristics
Data are shown as N (%) or Mean (SD); BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin A1c; eGFR, 
estimated glomerular filtration rate; LDL, low density lipoprotein; DPP4i, dipeptidyl-peptidase-4 inhibitor; ACEI/ARB, angiotensin converting enzyme inhibitor/
angiotensin receptor blocker
Participants Number of events per participant P (trend)
0 1  ≥ 2
Randomized 9901 8233 1425 243
Mean age (years) 9901 65.8 (6.3) 68.1 (7.3) 67.9 (8.0)  < 0.0001
Female 4589 3972 (48.2) 522 (36.6) 95 (39.1)  < 0.0001
White 7498 6207 (75.4) 1096 (76.9) 195 (80.3) 0.044
Tobacco consumption 1407 1113 (13.5) 254 (17.8) 40 (16.5)  < 0.0001
Prior cardiovascular disease 3114 2362 (28.7) 614 (43.1) 138 (56.8)  < 0.0001
Hypertension 9224 7658 (93.0) 1338 (93.9) 228 (93.8) 0.23
Prior heart failure 853 626 (7.6) 184 (12.9) 43 (17.7)  < 0.0001
Mean diabetes duration (years) 9901 10.3 (7.04) 11.4 (7.91) 11.8 (8.67)  < 0.0001
Mean BMI (kg/m2) 9900 32.4 (5.7) 32.0 (5.78) 32.6 (6.12) 0.16
Mean SBP (mm Hg) 9901 137 (16.5) 140 (18.0) 139 (17.7)  < 0.0001
Mean DBP (mm Hg) 9901 78.5 (9.7) 78.6 (10.3) 77.2 (10.6) 0.463
Mean HbA1c 9876 7.3 (1.0) 7.4 (1.1) 7.4 (1.0) 0.0062
Mean eGFR (mL/min per 1.73  m2) 9640 77.9 (22.3) 71.7 (24.0) 70.7 (23.8)  < 0.0001
Mean LDL (mmol/L) 9590 2.55 (0.97) 2.64 (1.00) 2.48 (0.96) 0.092
Medications
 Metformin 8037 6737 (81.8) 1111 (78.0) 189 (77.8) 0.0004
 Sulfonylurea 4552 3740 (45.4) 700 (49.1) 112 (46.1) 0.0430
 Insulin 2363 1889 (22.9) 409 (28.7) 65 (26.8)  < 0.0001
 DPP4i 564 484 (5.9) 64 (4.5) 16 (6.6) 0.220
 Thiazolidinedione 168 150 (1.8) 14 (1.0) 4 (1.7) 0.073
 Other glucose lowering drugs 32 28 (0.3) 4 (0.3) 0 0.39
 ACEI/ARB 8068 6700 (81.4) 1166 (81.8) 202 (83.1) 0.47
 Beta blocker 4512 3628 (44.1) 737 (51.7) 147 (60.5)  < 0.0001
 Other BP drug 5599 4568 (55.5) 871 (61.1) 160 (65.8)  < 0.0001
 Statin 6547 5450 (66.2) 907 (63.7) 190 (78.2) 0.27
 Fibrate 898 756 (9.2) 119 (8.4) 23 (9.5) 0.52
 Antiplatelet 5342 4365 (53.0) 812 (57.0) 165 (67.9)  < 0.0001
Table 2 Incidences and hazard ratios of the composites of total CV events or non-CV deaths
a Difference in numbers (and rate) of outcomes in the dulaglutide group versus the placebo group; N, number of outcomes; py, person-year; MACE, major adverse 
cardiovascular events; CV, cardiovascular; UA, unstable angina; HF, heart failure; Revasc, revascularization




N (/1000py) N (/1000py) N (N/1000py) HR (95% CI) p HR (95% CI) P
MACE or non‑CV death 932 (35.8) 1040 (40.3) 108 (4.5) 0.90 (0.82–0.98) 0.020 0.89 (0.80–0.98) 0.022
MACE, UA or non‑CV death 1034 (39.7) 1123 (43.5) 89 (3.8) 0.92 (0.85–1.00) 0.052 0.91 (0.83–1.01) 0.066
MACE, HF or non‑CV death 1195 (45.9) 1372 (53.2) 177 (7.3) 0.91 (0.84–0.99) 0.021 0.86 (0.78–0.96) 0.006
MACE, Revasc or non‑CV death 1399 (53.8) 1519 (58.9) 120 (5.1) 0.92 (0.86–0.99) 0.030 0.91 (0.83–1.01) 0.0632
MACE, UA, HF, Revasc or non‑CV death 1747 (67.1) 1926 (74.7) 179 (7.6) 0.93 (0.87–0.99) 0.023 0.90 (0.82–0.99) 0.028
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randomized to placebo. Moreover, the reduction in abso-
lute numbers of events was greater for expanded MACE 
or non-CV deaths than for MACE or non-CV deaths in 
the dulaglutide treatment group.
The pre-specified primary analyses of all CV outcomes 
trials with GLP-1 receptor agonists, including REWIND, 
focused on estimating a participant’s risk of experiencing 
the first primary CV outcome, MACE after randomiza-
tion. The reported HRs therefore reflect differences in the 
time from randomization to the first outcome in people 
who were randomly assigned to the active versus control 
therapy. The previously reported HR of 0.88 for dulaglu-
tide versus placebo in the REWIND trial means that on 
average at any time-point after randomization, people 
who had been randomly assigned to dulaglutide were 12% 
less likely to have experienced a first post-randomization 
MACE than people who had been randomized to pla-
cebo [4]. Although this provides important information 
regarding the therapeutic effect of dulaglutide, patients 
and health care providers are also interested in know-
ing the total burden of serious CV events, and deaths 
from any cause in participants treated with dulaglutide. 
The estimated HR of about 0.9 for the burden of total 
MACE or non-CV death therefore focuses on events and 
not participants. It means that at any time-point after 
randomization, there were 10% fewer events in people 
randomly assigned to dulaglutide versus placebo. In the 
participants with a placebo-group MACE or non-CV 
death rate of 40.3 per 1000 py, this 10% difference would 
be consistent with 108 fewer MACE or non-CV deaths, 
and 179 fewer expanded MACE or non-CV deaths (with 
a placebo rate of 74.7 per 1000 py) in the dulaglutide 
group during the 5.4-year follow-up. If the results of this 
post hoc analysis are replicated, we hypothesize that the 
number of events avoided would be higher in individuals 
with event rates higher than those reported in Table 2.
The inclusion of non-CV death within the primary 
analyses presented here represents a conservative 
approach to estimating the effect of dulaglutide on the 
overall burden of CV disease as well as on the time 
to the first occurrence. First, death from any cause is 
clearly relevant to both participants and providers. 
Fig. 1 Cumulative incidence of the composite of total MACE or non‑CV deaths (a) and the composite of total expanded MACE or non‑CV deaths 
(b) in the dulaglutide group (blue line) and the placebo group (red line) during the follow‑up. The hazard ratios (HR) are from the proportional 
means model
Table 3 Estimated effects of dulaglutide on the first composite outcome
a Difference in numbers (and rate) of people experiencing a first composite event in the dulaglutide group versus the placebo group; CV, cardiovascular; py, person-
year; MACE, major adverse cardiovascular events; UA, unstable angina; HF, heart failure; Revasc, revascularization
Composite event Dulaglutide group Placebo group People  spareda Cox model
N (N/1000py) N (N/1000py) N (N/1000py) HR (95% CI) p
MACE or non‑CV death 789 (31.2) 879 (35.3) 90 (4.1) 0.88 (0.80, 0.97) 0.011
MACE, UA, or non‑CV death 859 (34.3) 933 (37.8) 74 (3.5) 0.91 (0.83, 0.99) 0.041
MACE, HF or non‑CV death 880 (35.3) 983 (40.1) 103 (4.8) 0.88 (0.80, 0.96) 0.0054
MACE, Revasc, or non‑CV death 1002 (40.8) 1090 (44.9) 88 (4.1) 0.91 (0.83, 0.99) 0.028
MACE, UA, HF, Revasc, or non‑CV death 1097 (45.3) 1189 (49.8) 92 (4.5) 0.91 (0.84, 0.99) 0.024
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Second, including all-cause deaths versus just CV 
deaths eliminates any misclassification of the cause 
of death (i.e. CV or non-CV death). Finally, it elimi-
nates the possibility that a benefit of the drug on event 
burden would be negated by an increase in death, 
also referred to as the competing risk of death [21]. 
Whereas some investigators addressed this possibil-
ity in sensitivity analyses [13–15], we and others have 
integrated all-cause death into the main analyses of 
event burden [16]. Notably, the estimated HR of 0.88 
for the time to the occurrence of the first MACE out-
come or non-CV death was identical to the previously 
reported HR for the first occurrence of MACE alone 
[4]. However, the addition of non-CV deaths increases 
the event rates in both treatment groups compared 
with MACE alone and hence the number of people 
spared from experiencing an event. This is reflected 
in the absolute risk reduction which was 3.1 per 1000 
py for the first occurrence of a MACE as previously 
reported (594 versus 663 events) [4], and 4.1 per 1000 
py for the first occurrence of a MACE or non-CV 
death as noted in Additional file 1: Table S3 (789 ver-
sus 879 events).
The finding of a reduced burden of CV events 
in the REWIND trial is similar to the results of an 
analysis of event burden from the Liraglutide Effect 
and Action in Diabetes Evaluation of cardiovascular 
Results (LEADER) trial of another GLP-1 RA. In this 
analysis liraglutide was associated with a reduction of 
total (first and recurrent) MACE by 16% and of total 
CV events by 13% in 9340 participants followed for a 
median of 3.8  years [15]. Notably, inclusion of non-
CV deaths in a sensitivity analysis did not alter their 
findings. The higher outcome reduction rates in the 
LEADER trial than in the REWIND mostly result in 
a higher risk population; indeed, 83% of the LEADER 
enrolled participants had a chronic CV disease com-
pared with 31% of the REWIND enrolled participants.
Although the exact mechanism of the benefit of 
dulaglutide or other GLP-1 receptor agonists on CV 
disease reduction is unknown, possibilities include 
a decrease of risk factors such as high HbA1c, LDL-
cholesterol, blood pressure and bodyweight as well as 
potential effects on the atherothrombotic process by 
improving endothelial and platelet functions [22] and 
attenuating the arterial plaque progression by reduc-
ing inflammation and vascular tone [23]. The fact that 
other GLP-1 receptor agonists such as liraglutide and 
semaglutide have qualitatively similar effects on CV 
events, metabolic and other indices overall and within 
sub-groups is consistent with general “class effect” of 
these drugs [24–26].
Limitations
These analyses are limited by the fact that they were 
not pre-specified and causal conclusions should not 
be drawn. Strengths include the 5.4-year median fol-
low-up period, the large number of participants from 
many countries with well characterized baseline clinical 
findings, the high proportion of enrolled women, and 
the inclusion of all deaths in the composite event as a 
measure of total event burden.
Conclusions
These findings suggest that dulaglutide reduced the 
event burden of CV or fatal outcomes in a population at 
moderate CV risk. The absolute reduction was greatest 
for the composite outcome that included an expanded 
definition of a MACE. Our study supports the clinical 
implication of assessing all CV events or deaths in addi-
tion to the first manifestation of the primary outcome 
of randomized trials to capture the impact of the phar-
macological intervention on the burden of disease.
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